Catherine Novack
Stock Analyst at JonesTrading
(4.71)
# 744
Out of 4,575 analysts
138
Total ratings
41.8%
Success rate
26.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Catherine Novack
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Downgraded: Hold | $97 → $85 | $83.73 | +1.52% | 17 | Jul 7, 2026 | |
| PRQR ProQR Therapeutics | Maintained: Buy | $11 → $10 | $1.72 | +481.40% | 4 | Jun 26, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $135 | $43.08 | +213.37% | 1 | Jun 8, 2026 | |
| RZLT Rezolute | Reiterated: Buy | $6 | $4.99 | +20.24% | 8 | Jun 2, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $35 | $5.81 | +502.41% | 14 | May 19, 2026 | |
| IBIO iBio, Inc. | Maintained: Buy | $7 | $1.43 | +389.51% | 2 | May 13, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Buy | $29 → $51 | $19.70 | +158.88% | 9 | May 13, 2026 | |
| KRRO Korro Bio | Upgraded: Buy | $23 | $10.64 | +116.17% | 3 | May 8, 2026 | |
| DTIL Precision BioSciences | Initiated Coverage: Buy | $30 | $7.29 | +311.52% | 2 | Apr 16, 2026 | |
| TSX: MDNA Medicenna Therapeutics Corp. | Rated: Hold | n/a | $0.35 | - | 4 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.31 | - | 10 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $13 | $4.00 | +225.00% | 9 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $143 → $209 | $138.01 | +51.44% | 7 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $43 | $33.10 | +29.91% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $33 | $6.32 | +422.15% | 1 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $9 | $1.52 | +492.11% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $24.44 | n/a | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $6 | $3.71 | n/a | 8 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $1.28 | n/a | 6 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $0.7599 | n/a | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.49 | n/a | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 → $60 | $1.43 | n/a | 4 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $5.94 | n/a | 4 | Nov 15, 2021 |
Crinetics Pharmaceuticals
Jul 7, 2026
Downgraded: Hold
Price Target: $97 → $85
Current: $83.73
Upside: +1.52%
ProQR Therapeutics
Jun 26, 2026
Maintained: Buy
Price Target: $11 → $10
Current: $1.72
Upside: +481.40%
Spruce Biosciences
Jun 8, 2026
Initiated Coverage: Buy
Price Target: $135
Current: $43.08
Upside: +213.37%
Rezolute
Jun 2, 2026
Reiterated: Buy
Price Target: $6
Current: $4.99
Upside: +20.24%
Wave Life Sciences
May 19, 2026
Reiterated: Buy
Price Target: $35
Current: $5.81
Upside: +502.41%
iBio, Inc.
May 13, 2026
Maintained: Buy
Price Target: $7
Current: $1.43
Upside: +389.51%
Capricor Therapeutics
May 13, 2026
Reiterated: Buy
Price Target: $29 → $51
Current: $19.70
Upside: +158.88%
Korro Bio
May 8, 2026
Upgraded: Buy
Price Target: $23
Current: $10.64
Upside: +116.17%
Precision BioSciences
Apr 16, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $7.29
Upside: +311.52%
Medicenna Therapeutics Corp.
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $0.35
Upside: -
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $16.31
Upside: -
Feb 24, 2026
Maintained: Buy
Price Target: $7 → $13
Current: $4.00
Upside: +225.00%
Feb 24, 2026
Maintained: Buy
Price Target: $143 → $209
Current: $138.01
Upside: +51.44%
Dec 23, 2025
Initiated Coverage: Buy
Price Target: $43
Current: $33.10
Upside: +29.91%
Sep 30, 2025
Initiated Coverage: Buy
Price Target: $33
Current: $6.32
Upside: +422.15%
Aug 8, 2025
Maintained: Buy
Price Target: $6 → $9
Current: $1.52
Upside: +492.11%
Jun 25, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $24.44
Upside: n/a
May 13, 2025
Maintained: Buy
Price Target: $10 → $6
Current: $3.71
Upside: n/a
Nov 15, 2024
Reiterated: Buy
Price Target: $13
Current: $1.28
Upside: n/a
Nov 15, 2024
Reiterated: Buy
Price Target: $15
Current: $0.7599
Upside: n/a
Oct 31, 2024
Downgraded: Hold
Price Target: n/a
Current: $2.49
Upside: n/a
Jun 3, 2024
Maintained: Buy
Price Target: $160 → $60
Current: $1.43
Upside: n/a
Nov 15, 2021
Downgraded: Hold
Price Target: n/a
Current: $5.94
Upside: n/a